Tenofovir/Levonorgestrel Intravaginal Ring and Tenofovir Intravaginal Ring

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-12

Study Completion Date

2020-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the safety, pharmacokinetics and pharmacodynamics of, and the tolerability and acceptance of an intravaginal ring (IVR) delivering both tenofovir and levonorgestrel (TFV/LNG) and an IVR delivering TFV only, compared to a placebo IVR, in women in Western Kenya.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)

NCT02762617

Healthy HIV

TERMINATED PHASE1

Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel

NCT01768962

HIV Prevention

COMPLETED PHASE1

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring

NCT02006264

HIV

COMPLETED PHASE1

Safety and Acceptability of a Vaginal Microbicide

NCT00111943

HIV Infections Hepatitis B, Chronic

COMPLETED PHASE2

Study of Dapivirine Vaginal Ring (VR) in Adolescents

NCT02028338

Human Immunodeficiency Virus

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Phase 2a clinical trial will evaluate the safety, pharmacokinetics and pharmacodynamics of, and the tolerability and adherence to two novel intravaginal rings (IVRs). The tenofovir/levonorgestrel (TFV/LNG) IVR and TFV IVRs are designed to provide HIV (and HSV-2) prevention with and without contraceptive for pregnancy prevention, respectively. Women will be protected from pregnancy by abstinence from vaginal intercourse or agreeing to consistently use condoms; concurrent use of a non-hormonal copper intrauterine device is permitted.

The study will enroll healthy, HIV-negative, non-pregnant, menstruating women aged 18-34 years, inclusive, and not currently infected with hepatitis B virus, who are assessed to be at lower risk for HIV. The goal is to enroll fifty (50) women in Western Kenya. The participants will be randomized 2:2:1 to use one of the following continuous delivery IVRs: twenty (20) women to use the TFV/LNG IVR; ten (10) women to use the TFV IVR; and ten (10) women to use the placebo IVR. Participants will attend up to ten (10) routine study visits that may include physical and pelvic exams, collection of venous blood, vaginal fluid and cervical mucus, and behavioral questionnaires. A subset of twenty (20) women will participate in in-depth interviews.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Contraception Prevention Anti-Retroviral Agent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TFV/LNG IVR (10mg/20μg) (Continuous)

Tenofovir/Levonorgestrel Intravaginal Ring

Group Type EXPERIMENTAL

TFV/LNG IVR

Intervention Type DRUG

TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.

TFV IVR (10mg) (Continuous)

Tenofovir Intravaginal Ring

Group Type EXPERIMENTAL

TFV IVR

Intervention Type DRUG

TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.

Placebo IVR (Non-eluting)

Placebo Intravaginal Ring

Group Type PLACEBO_COMPARATOR

Placebo IVR

Intervention Type DRUG

Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TFV/LNG IVR

TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.

Intervention Type DRUG

TFV IVR

TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.

Intervention Type DRUG

Placebo IVR

Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tenofovir/Levonorgestrel Intravaginal Ring Tenofovir Intravaginal Ring

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female, aged 18-34 years, inclusive
* General good health (by history and per clinician discretion) without any clinically significant systemic disease (including, but not limited to significant liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease, and diabetes), uterus, and cervix
* Not pregnant or planning to become pregnant
* Pre-screening HIV risk score ≤4
* Currently having regular menstrual cycles (approximately 24-35 days) OR with a history of having regular menstrual cycles before contraceptive use, by report, and resumed some menstruation or spotting (with biochemical confirmation of ovulation)
* Willing to undergo Visual Inspection with Lugol's Iodine (VILI) for cervical abnormalities during pelvic exam
* Willing to abstain from use of vaginal products other than the study product, including tampons (except for during menses) , menstrual cups, vaginally inserted cloths or other materials, spermicides, lubricants, and douches for the whole study
* Willing to abstain from any vaginal intercourse starting 48 hours before certain study visits
* Vaginal and cervical anatomy that, in the opinion of the clinician, lends itself to easy genital tract sample collection and is absent of vesicles and ulcers
* No use of hormonal contraceptives within the following periods specified for each type of contraception method:

* Oral contraceptives (combined or progestin-only), contraceptive patch or contraceptive vaginal ring in at least two (2) months
* Last DMPA injection received at least four (4) months ago and has resumed regular menstruation
* Hormonal IUD/IUS removed at least four (4) months ago and has resumed regular menstruation
* Hormonal implant removed at least six (6) months ago and has resumed regular menstruation
* Willing to refrain from using any hormonal contraceptives for the entire study and to use only study-provided non-spermicidal male condoms with or without a study-provided Cu-IUD
* P4 ≥3.0 ng/ml
* Estimated glomerular filtration rate (eGFR) ≥90ml/min/1.73m2
* Willing to give voluntary consent and sign/mark an informed consent form
* Willing and able to comply with protocol requirements

Exclusion Criteria

* Body mass index (BMI) ≥30 kg/m
* History of hysterectomy
* Currently pregnant or within less than three (3) calendar months of the last pregnancy outcome.
* Currently breastfeeding or having breastfed an infant in the last two (2) months, or planning to breastfeed during the course of the study
* Contraindication to any study products-LNG, TFV, or excipient ingredients
* Contraindication to LNG
* In the last three (3) months, diagnosed with or treated for any STI or pelvic inflammatory disease
* Positive test for HIV-1, syphilis, Trichomonas vaginalis (TV), Neisseria gonorrhea (GC), Chlamydia trachomatis (CT) or HBsAg
* Nugent score greater than or equal to 7 or a symptomatic BV clinical diagnosis as defined by Amsel's criteria
* Suspected breast cancer or other progestin-sensitive cancer
* Suspected hepatic disease, including cirrhosis or viral hepatitis
* History of bleeding or coagulation problems
* Known current drug or alcohol abuse which could impact study compliance
* Grade 2 or higher laboratory abnormality, per the Division of AIDS, National Institute of Allergy and Infectious Disease (DAIDS) Table for Grading the Severity of Adverse Events, or clinically significant laboratory abnormality as determined by the clinician
* Use of any concomitant medications
* Participation in any other investigational trial with use of a drug/device within the last 30 days or planned participation in any other investigational trial with use of a drug/device during the study
* History of gynecological procedures (including genital piercing) on the external genitalia, vagina, or cervix within the last 14 days
* Labial elongation (due to pulling practices and use of botanicals or caustic agents)
* Abnormal finding on laboratory or physical examination or a social or medical condition in the volunteer which, in the opinion of the site co-PI(s), would make participation in the study unsafe or would complicate interpretation of data
* Currently using, or has used within the preceding one (1) month, emtricitabine/tenofovir disoproxil fumarate (TDF/FTC or Truvada®) or any other tenofovir product, and/or has plans to use a non-study tenofovir product in any form during the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

34 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes